Literature DB >> 9559895

A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity.

R L Handy1, P K Moore.   

Abstract

1. Intraplantar injection of carrageenan (150 microl, 1-3% w/v) in the rat resulted in a dose-related increase in hindpaw weight (oedema) characterized by a rapid 'early' phase (up to 2.5 h) response followed by a more sustained 'late' phase (2-6 h) response. No change in weight of either the contralateral (i.e. noninjected) hindpaw or hindpaws injected with saline was observed. 2. Six hours after intraplantar injection of carrageenan (1-3% w/v) hindpaw constitutive (i.e. calcium-dependent) nitric oxide synthase (cNOS) activity (determined ex vivo as the conversion of radiolabelled L-arginine to radiolabelled citrulline) was increased (e.g. 2% w/v; 0.64+/-0.08 pmol citrulline mg(-1) protein 15 min(-1) c.f. 0.08+/-0.04 pmol citrulline mg(-1) protein 15 min(-1) in saline-injected, control animals, n=4, P<0.05). Carrageenan injection also resulted in the appearance in hindpaw homogenates of inducible (i.e. calcium-independent) nitric oxide synthase (iNOS, e.g. 2% w/v; 0.67+/-0.14 pmol citrulline mg(-1) protein 15 min(-1), n=4). Hindpaw cyclic GMP concentration was also significantly increased 6 h after intraplantar injection of carrageenan (e.g. 2% w/v; 379.6+/-26.8 fmol mg(-1) protein c.f. 261.8+/-42.2 fmol mg(-1) protein, in saline-injected, control animals, n=4, P<0.05). 3. Pretreatment (5-25 mg kg(-1), i.p., 30 min before carrageenan, 2% w/v) of animals with L-N(G) nitro arginine methyl ester (L-NAME; isoform nonselective inhibitor of NOS) or 7-nitro indazole (7-NI; inhibitor of neuronal NOS, nNOS) caused dose-related inhibition of both the early (2 h) and late (6 h) phase hindpaw oedema, associated with reduced hindpaw iNOS and cNOS activity and cyclic GMP concentration in animals killed at 6 h. Administration of 7-NI (5-25 mg kg(-1), i.p.) to animals 2.5 h after intraplantar carrageenan (2% w/v) injection (i.e. at the end of the early phase oedema response) produced dose-related inhibition of the late phase response. 4. Pretreatment (5-25 mg kg(-1), i.p., 30 min before carrageenan, 2% w/v) of animals with L-N6-iminoethyllysine (L-NIL, selective inhibitor of iNOS) (5-25 mg kg(-1)) failed to affect the early phase hindpaw oedema response but did produce a dose-related inhibition of the late phase oedema. L-NIL pretreatment also inhibited the carrageenan-induced increase in both hindpaw iNOS and cNOS activity as well as the rise in hindpaw cyclic GMP concentration. 5. The present experiments demonstrate an anti-inflammatory effect of 7-NI as evidenced by inhibition of carrageenan-induced hindpaw oedema in the rat. Inhibition of nNOS (early phase) and iNOS (late phase) at the site of inflammation most probably accounts for the anti-inflammatory activity observed. These data suggest a role for nitric oxide synthesized by the nNOS isoform (most probably within sensory nerves) in this model of inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559895      PMCID: PMC1565282          DOI: 10.1038/sj.bjp.0701735

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.

Authors:  Felipe F Rodrigues; Marcela I Morais; Ivo S F Melo; Paulo S A Augusto; Marcela M G B Dutra; Sarah O A M Costa; Fábio C Costa; Franciele A Goulart; Alysson V Braga; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-11-25       Impact factor: 4.473

2.  Effect of fish or soybean oil-rich diets on bradykinin, kallikrein, nitric oxide, leptin, corticosterone and macrophages in carrageenan stimulated rats.

Authors:  Marta Wohlers; Roberta Araujo Navarro Xavier; Lila Missae Oyama; Eliane Beraldi Ribeiro; Cláudia Maria Oller do Nascimento; Dulce Elena Casarini; Vera Lucia Flor Silveira
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

3.  The antioxidant effects of isorhamnetin contribute to inhibit COX-2 expression in response to inflammation: a potential role of HO-1.

Authors:  Kyuhwa Seo; Ji Hye Yang; Sang Chan Kim; Sae Kwang Ku; Sung Hwan Ki; Sang Mi Shin
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 4.  Nitric oxide synthases: structure, function and inhibition.

Authors:  W K Alderton; C E Cooper; R G Knowles
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

5.  Capnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in rats.

Authors:  Yen-Hsuan Jean; Wu-Fu Chen; Chun-Sung Sung; Chang-Yih Duh; Shi-Ying Huang; Chan-Shing Lin; Ming-Hon Tai; Shun-Fen Tzeng; Zhi-Hong Wen
Journal:  Br J Pharmacol       Date:  2009-08-05       Impact factor: 8.739

6.  Effects of aminoguanidine on nitric oxide production induced by inflammatory cytokines and endotoxin in cultured rat hepatocytes.

Authors:  G L Zhang; Y H Wang; H L Teng; Z B Lin
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

7.  Hydrogen sulphide is a mediator of carrageenan-induced hindpaw oedema in the rat.

Authors:  Madhav Bhatia; Jenab Sidhapuriwala; Shabbir M Moochhala; Philip K Moore
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  Dual role of nNOS in ischemic injury and preconditioning.

Authors:  Anupama Barua; Nicholas B Standen; Manuel Galiñanes
Journal:  BMC Physiol       Date:  2010-08-13

9.  Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo.

Authors:  J D Bradley; D G Cleverly; A M Burns; N B Helm; M J Schmid; D B Marx; D M Cullen; R A Reinhardt
Journal:  J Periodontal Res       Date:  2007-06       Impact factor: 4.419

10.  Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production.

Authors:  Y W Kim; R J Zhao; S J Park; J R Lee; I J Cho; C H Yang; S G Kim; S C Kim
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.